Paper Details

  1. Home
  2. Paper Details

Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

Author: , AltaweelMichael M, DanielEbenezer, FerrisFrederick L, FineStuart L, GrunwaldJuan E, HuangJiayan, LaiMichael M, MaguireMaureen G, MartinDaniel F, MelamudAlexander, MittraRobert A, MorseLawrence S

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This prospective cohort study of 1185 patients enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) found that eyes with >50% of the lesion composed of blood had a visual prognosis similar to eyes with less or no blood. Lesion size decreased markedly through 2 years.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of blood (B50 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/25307130

データ提供：米国国立医学図書館（NLM）

Age-Related Macular Degeneration: Navigating a Complex Landscape

The [age-related macular degeneration (AMD)] research field is a complex and ever-evolving landscape, with researchers constantly seeking new strategies to combat this debilitating condition. This study focuses on [patients with neovascular AMD] and examines the [impact of lesions containing a high percentage of blood] on [treatment outcomes], specifically exploring the [differences in visual acuity and lesion characteristics] between patients with [lesions composed of >50% blood] and those with [other types of lesions].

Navigating the Blood-Filled Oasis of Neovascular AMD

The study found that while [lesions with high blood content] may have [different baseline characteristics], patients with [these lesions] experienced [similar visual improvement] at [1 and 2 years] compared to those with [other types of lesions]. This finding provides valuable insights into the [management of neovascular AMD] and suggests that [patients with blood-rich lesions] can be treated with [similar approaches] as those with [other lesion types].

Age-Related Macular Degeneration: A Desert of Challenges, But Hope Remains

This study provides valuable insights for treating [patients with neovascular AMD], specifically those with [lesions composed of >50% blood]. It suggests that [these patients] can be [managed effectively] using similar approaches as those with [other types of lesions]. This research continues to [advance our understanding] of this complex condition and bring hope for a [brighter future] for patients with [AMD].

Dr.Camel's Conclusion

This study provides encouraging news for individuals with neovascular AMD, demonstrating that lesions composed of >50% blood can be effectively managed using similar treatment approaches as those with other types of lesions. This is a significant step forward in understanding and treating this debilitating condition, offering hope for improved visual outcomes and a better quality of life for patients.

Date :
  1. Date Completed 2015-04-14
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

25307130

DOI: Digital Object Identifier

NIHMS627520

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.